Alumis Inc. is a cutting-edge technology company specializing in the development and commercialization of innovative solutions within the healthcare sector. Focused on enhancing patient care and operational efficiencies, the company harnesses advanced data analytics and artificial intelligence to provide healthcare providers with actionable insights and tools. Their offerings aim to improve patient outcomes, streamline workflows, and reduce costs, positioning Alumis as a key player in the transformation of healthcare services. Through their commitment to research and development, the company strives to address the evolving needs of the medical community and empower healthcare professionals with the resources necessary for excellence in care delivery. Read More
The first week of 2026 has delivered a definitive verdict on the next phase of the bull market: the era of mega-cap dominance is yielding to the rise of the small-cap. In a dramatic "Great Rotation," investors are pulling capital from the expensive, AI-saturated titans of the Nasdaq and pouring
Synergy CHC Corp. (NASDAQ: SNYR) is gaining renewed investor attention as its FOCUSfactor® functional beverage platform scales rapidly through the Company’s already-established retail ecosystem—built on the strength of its 25-year FOCUSfactor® brain health supplement legacy . By leveraging long-standing national distribution relationships, Synergy is accelerating beverage adoption without the execution risk typically associated with launching a new consumer brand.This beverage expansion underpins Roth Capital Partners’ Buy rating and 12-month $7 price target on SNYR. Roth projects revenues could grow from approximately $35.4 million in 2025 to nearly $55 million in 2026, driven largely by beverage penetration layered onto Synergy’s existing retail and wholesale channels.
– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis –
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company’s special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company’s merger agreement with Alumis Inc. (Nasdaq: ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction.
